Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

5.8K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.8K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

13.3K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
Histone Modification02:32

Histone Modification

16.4K
The histone proteins have a flexible N-terminal tail extending out from the nucleosome. These histone tails are often subjected to post-translational modifications such as acetylation, methylation, phosphorylation, and ubiquitination. Particular combinations of these modifications form “histone codes” that influence the chromatin folding and tissue-specific gene expression.
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone...
16.4K
Chromatin Modification in iPS Cells01:32

Chromatin Modification in iPS Cells

2.2K
Chromatin modification alters gene expression; therefore, scientists can add histone-modifying enzymes, histone variants, and chromatin remodeling complexes to somatic cells to aid reprogramming into pluripotent stem (iPS) cells.
Compact chromatin makes reprogramming difficult. Enzymes, such as histone demethylases and acetyltransferases, are often added during reprogramming to loosen the chromatin, making the DNA more accessible to transcription factors. Molecules that inhibit histone...
2.2K
Phosphoinositides and PIPs01:42

Phosphoinositides and PIPs

10.4K
Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
10.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editor's Note: TRIM59 Promotes Gliomagenesis by Inhibiting TC45 Dephosphorylation of STAT3.

Cancer research·2025
Same author

Nucleoli and the nucleoli-centromere association are dynamic during normal development and in cancer.

Molecular biology of the cell·2023
Same author

LY6K promotes glioblastoma tumorigenicity via CAV-1-mediated ERK1/2 signaling enhancement.

Neuro-oncology·2020
Same author

TGF-β-activated lncRNA LINC00115 is a critical regulator of glioma stem-like cell tumorigenicity.

EMBO reports·2019
Same author

CDK5-dependent phosphorylation and nuclear translocation of TRIM59 promotes macroH2A1 ubiquitination and tumorigenicity.

Nature communications·2019
Same author

Correction to: Lipolytic inhibitor G0S2 modulates glioma stem-like cell radiation response.

Journal of experimental & clinical cancer research : CR·2019

Related Experiment Video

Updated: Feb 21, 2026

Assays for Validating Histone Acetyltransferase Inhibitors
09:11

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

7.0K

Histone Acetyltransferase KAT6A Upregulates PI3K/AKT Signaling through TRIM24 Binding.

Deguan Lv1,2, Feng Jia3, Yanli Hou4

  • 1State Key Laboratory of Oncogenes and Related Genes, Renji-Med X Clinical Stem Cell Research Center, Ren Ji Hospital, School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, China.

Cancer Research
|October 13, 2017
PubMed
Summary

Lysine acetyltransferase KAT6A promotes glioblastoma (GBM) by acetylating histone H3, recruiting TRIM24, and activating PIK3CA. This pathway enhances PI3K/AKT signaling, driving tumor growth and indicating KAT6A as a potential GBM therapeutic target.

More Related Videos

Author Spotlight: Developing Acetyl-Click Assay for HAT1 Inhibitor Screening
05:44

Author Spotlight: Developing Acetyl-Click Assay for HAT1 Inhibitor Screening

Published on: January 26, 2024

1.4K
Deacetylation Assays to Unravel the Interplay between Sirtuins SIRT2 and Specific Protein-substrates
14:32

Deacetylation Assays to Unravel the Interplay between Sirtuins SIRT2 and Specific Protein-substrates

Published on: February 27, 2016

8.7K

Related Experiment Videos

Last Updated: Feb 21, 2026

Assays for Validating Histone Acetyltransferase Inhibitors
09:11

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

7.0K
Author Spotlight: Developing Acetyl-Click Assay for HAT1 Inhibitor Screening
05:44

Author Spotlight: Developing Acetyl-Click Assay for HAT1 Inhibitor Screening

Published on: January 26, 2024

1.4K
Deacetylation Assays to Unravel the Interplay between Sirtuins SIRT2 and Specific Protein-substrates
14:32

Deacetylation Assays to Unravel the Interplay between Sirtuins SIRT2 and Specific Protein-substrates

Published on: February 27, 2016

8.7K

Area of Science:

  • Oncology
  • Epigenetics
  • Molecular Biology

Background:

  • Lysine acetyltransferase KAT6A is a chromatin regulator implicated in cancer.
  • The precise mechanisms underlying KAT6A's role in tumorigenesis remain unclear.
  • KAT6A is frequently upregulated in glioblastoma (GBM), a highly aggressive brain tumor.

Purpose of the Study:

  • To elucidate the signaling pathway by which KAT6A contributes to glioblastoma development.
  • To investigate the potential of KAT6A as a therapeutic target for GBM.

Main Methods:

  • Analysis of KAT6A expression in GBM patient data.
  • In vitro cell proliferation, migration, and colony formation assays.
  • Orthotopic mouse xenograft models to assess tumor development.
  • Mechanistic studies involving histone acetylation, protein recruitment, gene transcription, and signaling pathway analysis.
  • Assessment of mutant KAT6A and TRIM24 proteins.

Main Results:

  • KAT6A expression correlates with poor GBM patient survival.
  • KAT6A silencing inhibits GBM cell proliferation, migration, and tumor growth in vivo.
  • KAT6A acetylates histone H3 at lysine 23 (H3K23), recruiting TRIM24.
  • This interaction activates PIK3CA transcription, boosting PI3K/AKT signaling and promoting tumorigenesis.
  • Specific KAT6A and TRIM24 domains are crucial for promoting PIK3CA expression and cell proliferation.

Conclusions:

  • KAT6A plays a critical role in glioma formation through the H3K23ac-TRIM24-PIK3CA axis.
  • Targeting KAT6A presents a promising therapeutic strategy for glioblastoma.